Your session is about to expire
← Back to Search
Pembrolizumab + Vorinostat for Lung Cancer
Study Summary
This trial is testing whether combining two drugs, pembrolizumab and vorinostat, can help people with advanced lung cancer.
Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2024 Phase 2 trial • 57 Patients • NCT03004183Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I have a history of tuberculosis.I have previously received treatments targeting the immune system for cancer.I have an immune system disorder or have been on high-dose steroids or other immune-weakening medicines recently.I received chest radiation of more than 30Gy less than 6 months ago.I haven't had any cancer antibody treatments in the last 4 weeks or have recovered from their side effects.I have never been treated with drugs targeting the immune system for cancer.I haven't had chemotherapy in the last 3 weeks or targeted therapy/radiation in the last 2 weeks, and I've recovered from previous treatment side effects.Your tumor has a PD-L1 score of at least 1%.I am fully active or restricted in physically strenuous activity but can do light work.My diagnosis is Stage IV non-small cell lung cancer.You have a measurable tumor according to specific guidelines for evaluating tumors.I have been diagnosed with interstitial lung disease.My condition worsened after at least one treatment.I haven't received treatment for stage IV cancer, except targeted therapy for specific mutations.My organs are functioning well.I agree to use barrier contraception during and for 120 days after the study.I have been treated for an autoimmune disease in the last 2 years.I have or had lung inflammation treated with steroids.I have a history of heart failure that affects my daily activities.I am not taking any HDAC inhibitors except for vorinostat.I have not received a live vaccine in the last 30 days.I am 18 years old or older.You have a current, active infection of Hepatitis B or Hepatitis C.I am currently being treated for an infection.I am willing to provide a new tissue sample from my tumor for the study.I am not allergic to pembrolizumab, vorinostat, or their ingredients.I have another cancer that is getting worse or needs treatment.I have been diagnosed with HIV.I have fully recovered from any major surgery before starting treatment.I have cancer that has spread to my brain or spinal cord.I can provide tissue samples from previous biopsies if available.I am using two birth control methods or am not having sex to avoid pregnancy during and after the study.
- Group 1: Phase I Dose Escalation
- Group 2: Arm B: Pembrolizumab plus Vorinostat
- Group 3: Phase Ib Expansion
- Group 4: Arm A: Pembrolizumab
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Can you provide any information about prior experiments with Pembrolizumab?
"Presently, there are 986 clinical trials underway concerning Pembrolizumab. Of those studies, 124 are in their terminal Phase 3 stage of development. Although the majority of these investigations initiated from Sacramento, California; an expansive network of 36506 medical centres nationwide have joined the effort to study this drug's efficacy."
How many participants have been enrolled in this trial to date?
"This clinical trial is no longer actively enrolling patients. It was first uploaded on March 22nd 2016 and last updated November 10th 2022, but there are over 3000 current studies seeking participants with Non-Small cell lung cancer or Pembrolizumab."
Does this research project have any openings for participants at present?
"According to information listed on clinicaltrials.gov, this medical trial is not actively accepting participants at the current moment. Initially posted in March 2016 and last updated in November 2022, it appears that the recruitment period has ended; however, there are 3068 other studies currently recruiting patients worldwide."
Who else is applying?
What site did they apply to?
What portion of applicants met pre-screening criteria?
Share this study with friends
Copy Link
Messenger